US IRB approval of Collategene trial boosts AnGes
This article was originally published in Scrip
Executive Summary
Shares in AnGes MG spiked in Tokyo after the Japanese bioventure announced its US subsidiary had received final institutional review board (IRB) approval for a planned pilot trial with the firm's lead therapeutic candidate.